Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD T LEE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1255503850
CMS profile
102241
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$83.33

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $83.33 7

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $68.19 6
EISAI INC. $15.14 1

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD T LEE

NPI 1255503850 · CMS profile ID 102241

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255503850?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD T LEE, NPI 1255503850, CMS profile ID 102241. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255503850?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RICHARD T LEE, NPI 1255503850, CMS profile ID 102241. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255503850?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RICHARD T LEE, NPI 1255503850, CMS profile ID 102241, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1255503850?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $83.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $15.1410/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703088311 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.4707/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682096429 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.2903/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681885247 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.1802/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682061359 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.4702/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681745649 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.6301/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682079283 CMS
Takeda Pharmaceuticals U.S.A., Inc. $8.1501/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681732105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $83.33 7
PY2022 $116.86 5
PY2024 $25.08 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $13,052.78 2
PY2021 Principal investigator $13,857.39 4
PY2020 Principal investigator $22,502.00 18
PY2019 Principal investigator $88,558.05 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $21.40 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497329
Principal investigator 1 Incyte Corporation $171.20 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497331
Principal investigator 1 Incyte Corporation $28.94 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497333
Principal investigator 1 Incyte Corporation $133.25 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497335
Principal investigator 1 Incyte Corporation $15.40 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497337
Principal investigator 1 Incyte Corporation $53.50 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497339
Principal investigator 1 Incyte Corporation $85.60 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497341
Principal investigator 1 Incyte Corporation $20.00 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497343
Principal investigator 1 Incyte Corporation $25.70 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497345
Principal investigator 1 Incyte Corporation $1.25 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497347
Principal investigator 1 Incyte Corporation $30.00 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497349
Principal investigator 1 Incyte Corporation $61.75 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497351
Principal investigator 1 Incyte Corporation $52.12 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497353
Principal investigator 1 Incyte Corporation $103.60 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497355
Principal investigator 1 Incyte Corporation $21.40 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497377
Principal investigator 1 Incyte Corporation $21.40 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497379
Principal investigator 1 Incyte Corporation $171.20 12/09/2019 Covered Recipient Teaching Hospital
RAINBOW BABIES & CHILDRENS HOSPITAL
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666497381
Principal investigator 1 Merck Sharp & Dohme Corporation $2,044.40 09/20/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691456005
Principal investigator 1 Merck Sharp & Dohme Corporation $5,000.00 08/23/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691456009
Principal investigator 1 Merck Sharp & Dohme Corporation $16,385.00 07/19/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691456001
Principal investigator 1 Merck Sharp & Dohme Corporation $2,200.00 06/19/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691370321
Principal investigator 1 Merck Sharp & Dohme Corporation $295.00 06/17/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691344875
Principal investigator 1 Merck Sharp & Dohme Corporation $885.00 06/17/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691344879
Principal investigator 1 Merck Sharp & Dohme Corporation $295.00 06/14/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691344867
Principal investigator 1 Merck Sharp & Dohme Corporation $295.00 06/14/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691344873
Principal investigator 1 Merck Sharp & Dohme Corporation $21.28 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691375907
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691376249
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691377133
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691403007
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691403009
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691411733
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691411737
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691412169
Principal investigator 1 Merck Sharp & Dohme Corporation $21.28 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691412173
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691412177
Principal investigator 1 Merck Sharp & Dohme Corporation $4.66 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691412555
Principal investigator 1 Merck Sharp & Dohme Corporation $4.66 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691412872
Principal investigator 1 Merck Sharp & Dohme Corporation $46.92 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691412875
Principal investigator 1 Merck Sharp & Dohme Corporation $69.30 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691413079
Principal investigator 1 Merck Sharp & Dohme Corporation $46.92 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691414146
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691414151
Principal investigator 1 Merck Sharp & Dohme Corporation $6.12 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691414155
Principal investigator 1 Merck Sharp & Dohme Corporation $6.12 06/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691414159
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 06/03/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691431025
Principal investigator 1 Merck Sharp & Dohme Corporation $4,844.00 05/24/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691324699
Principal investigator 1 Merck Sharp & Dohme Corporation $27,065.60 04/01/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691456185
Principal investigator 1 Merck Sharp & Dohme Corporation $2,344.00 03/18/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691325454
Principal investigator 1 Merck Sharp & Dohme Corporation $4,544.00 02/25/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691325519
Principal investigator 1 Merck Sharp & Dohme Corporation $6,744.00 01/30/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691310857
Principal investigator 1 Merck Sharp & Dohme Corporation $829.54 01/28/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691413151
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 01/10/2019 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil Versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Metastatic Esophageal Carcinoma KEYNOTE-590 No dispute reported 06/30/2026 691310785